Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing JNCI CANCER SPECTRUM Vlessis, K., Purington, N., Chun, N., Haraldsdottir, S., Ford, J. M. 2020; 4 (1): pkz095

Abstract

The National Comprehensive Cancer Network (NCCN) recommends germline testing for pathogenic BRCA1/2 mutations identified by somatic tumor sequencing. The aim of this study was to explore whether patients at Stanford with somatic BRCA1/2 mutations were recommended germline testing in accordance with NCCN guidelines.We retrospectively collected all Stanford patients with BRCA1/2 mutations found by tumor sequencing. Medical records were reviewed for each patient to identify those recommended germline testing. A multivariable logistic regression model was fit associating baseline characteristics with whether or not a recommendation was made.Of 164 participants, 51 (31.1%) had no recommendation for germline testing. Of the 97 available germline-testing results, 54 (55.7%) were positive for pathogenic BRCA1/2 mutations. After adjusting for possible confounders, patients with genitourinary cancer (odds ratio [OR] = 0.03, 95% confidence interval [CI] = 0.00 to 0.03; P?=?.003), lung cancer (OR = 0.04, 95% CI = 0.01 to 0.21; P?

View details for DOI 10.1093/jncics/pkz095

View details for Web of Science ID 000523291600017

View details for PubMedID 32259017

View details for PubMedCentralID PMC7043298